BioSpace News Archive

Shares of Pompano Beach, Fla.-based BioStem Technologies are down more than 6 percent this morning following the company’s announcement it has launched a new life sciences subsidiary, the Amnion Division of BioStem Life Sciences focused on the development of amniotic tissue-based therapies.

Artios Pharma Limited, based in Cambridge, U.K., got a significant financial boost from Pfizer, AbbVie and Novartis through an $84 million (£65 million) Series B funding that will help advance its DNA Damage Response (DDR) programs for cancer treatments.

Japan-based Astellas plunked down nearly $109 million to snap up privately-held gene therapy company Quethera Limited and its novel treatments for glaucoma and other ocular disorders.

Shares of Gemphire Therapeutics have crashed 73 percent in premarket trading after the company revealed its mid-stage non-alcoholic fatty liver disease (NAFLD) treatment for pediatric patients actually worsened the disease in some patients.

Bexion Pharmaceuticals is not a household name as far as drugmakers go. But, this week the company and its investigational cancer treatment, BXQ-350, is receiving lots of mainstream media coverage as a potential game-changer.

Mississauga, Ontario-based Aralez Pharmaceuticals Inc. has entered into a stalking horse agreement to sell its assets to two separate companies, Nuvo Pharmaceuticals and Deerfield Management Companies. The beleaguered company will secure about $250 million for its assets from the sale as it files for bankruptcy.

Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the first patient has been dosed in the phase 1/2 study SOBI003-001.

For the fourth consecutive year, Tower MSA Partners is sponsoring WCI-TV, the televised coverage of WCI 2018.

With the expansion of healthcare reform and the increase in consumption, China’s medical health services have guided multi-dimensional innovation and advancement. It is estimated that by 2030, the scale of China’s health service industry will reach 16 trillion.

Mallinckrodt Pharmaceuticals will present on Wednesday, Sept. 5, 2018, at the Wells Fargo Securities 2018 Healthcare Conference at the Westin Copley Place, 10 Huntington Ave., Boston.